Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.49 |
| ▸ | GRK2 | P25098 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134734 | 1.00 | KDM1A (0.56) | KDM1AHRH3FFAR1HTR2AHTR2C | |
| SCHEMBL29302375 | 1.00 | KDM1A (0.56) | KDM1AHRH3FFAR1HTR2AHTR2C | |
| SCHEMBL4134736 | 1.00 | KDM1A (0.56) | KDM1AHRH3FFAR1HTR2AHTR2C | |
| SCHEMBL31330378 | 0.88 | KDM1A (0.54) | KDM1AHRH3FFAR1HTR2AHTR2C | |
| SCHEMBL4134864 | 0.85 | KDM1A (0.59) | KDM1AHRH3HTR2AHTR2CHTR2B | |
| SCHEMBL4134867 | 0.85 | KDM1A (0.59) | KDM1AHRH3HTR2AHTR2CHTR2B | |
| SCHEMBL25606213 | 0.85 | KDM1A (0.54) | KDM1AHRH3HTR2AHTR2CHTR2B | |
| SCHEMBL1817691 | 0.81 | ROCK2 (0.49) | KDM1AHRH3HTR2AHTR2CHTR2B | |
| SCHEMBL4717135 | 0.81 | SLC6A4 (0.57) | KDM1AHRH3HTR2AHTR2CHTR2B | |
| SCHEMBL1817686 | 0.81 | ROCK2 (0.49) | KDM1AHRH3HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3914256-B1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-11773101-B2 | GPR35 modulators | PROMETHEUS BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210380590-A1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES, INC. | 2021-12-09 | — | — | US | disclosed |
| US-11053251-B2 | GPR35 modulators | PROMETHEUS BIOSCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200239476-A1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES, INC. | 2020-07-30 | — | — | US | disclosed |
| US-20040116418-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2004-06-17 | — | — | US | disclosed |
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB | 2002-09-19 | — | — | US | disclosed |
| US-6376492-B1 | GUANIDINE DERIVATIVES | MEDIVIR AB (SE) | 2002-04-23 | — | — | US | disclosed |
| US-5849769-A | N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection | MEDIVIR AB (SE) | 1998-12-15 | — | — | US | disclosed |
| EP-0706514-B1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1998-11-18 | — | — | EP | disclosed |
| EP-0706514-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995006034-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1995-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380590-A1 | GPR35 MODULATORS | GPR35, GPR55, GPR65 | KDM1A 4493/4885HRH3 454/4885FFAR1 29/4885 |
| US-11053251-B2 | GPR35 modulators | GPR35, GPR55, GPR65 | KDM1A 4493/4885HRH3 454/4885FFAR1 29/4885 |
| US-11773101-B2 | GPR35 modulators | GPR35, GPR55, GPR65 | KDM1A 4493/4885HRH3 454/4885FFAR1 29/4885 |
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | POLRMT, POLM, POLR1E | KDM1A 1796/4885HRH3 1608/4885FFAR1 4724/4885 |
| US-20200239476-A1 | GPR35 MODULATORS | GPR35, GPR55, GPR65 | KDM1A 4493/4885HRH3 454/4885FFAR1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.